Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science''s promise by bringing novel medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen is committed to advancing science to dramatically improve people''s lives.
Amgen Mission
To serve patients
Amgen Quick Facts:
Headquarters
Thousand Oaks, California
Staff
Approximately 17,000 worldwide
Stock Listing
NASDAQ: AMGN
Chairman and CEO
Kevin W. Sharer
2008 Financial Highlights
Total revenue: $15.0 billion
Product sales: $14.7 billion
R&D investment: $2.9 billion
Address/Phone
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Main: (805) 447-1000
Media: (805) 447-4587
Investors: (805) 447-1060
Principal Products
Aranesp® (darbepoetin alfa)
Enbrel® (etanercept)
EPOGEN® (Epoetin alfa)
Neulasta® (pegfilgrastim)
NEUPOGEN® (Filgrastim)
Nplate™ (romiplostim)
Sensipar® (cinacalcet HCl)
Vectibix® (panitumumab)
For product information, including important safety information, visit www.amgen.com